{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:43:36Z","timestamp":1785386616099,"version":"3.55.0"},"reference-count":59,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Histone deacetylase inhibitors (HDACi) are an emerging class of epigenetic anticancer drugs that exert their activity through coordination to the catalytic Zn2+ ion within the active site of histone deacetylases (HDACs). Due to the limited isoform-selectivity of hydroxamic acid-based inhibitors, benzamide-based HDACi (BBHDACi) have been developed as subtype-selective alternatives. Clinically relevant representatives include Chidamide, Entinostat, Mocetinostat, Zabadinostat, and Tacedinaline. Although these compounds share a conserved o-aminoanilide zinc-binding group (ZBG), they differ in linker and cap region structure, raising questions regarding their intrinsic Zn2+ affinity and coordination behavior. Herein, density functional theory (DFT) calculations were performed at the B3LYP\/6-311++g(d,p) level of theory combined with the PCM solvation in methanol (\u03b5 = 33) and water (\u03b5 = 78). Geometry optimization confirmed that the trans (E) isomer of Chidamide is thermodynamically preferred. Coordination studies showed that the remaining BBHDACi adopt stable geometries, with the o-aminoanilide group preferentially forming tetracoordinated complexes that are more stable than hexacoordinated ones in polar media. Interestingly, calculated substitution free energies differed by less than \u00b1 2 kcal.mol\u22121, indicating nearly identical intrinsic Zn2+ affinities across the series. These results suggest that the ZBG contributes similarly to metal coordination across all BBHDACi, whereas the overall binding strength is mainly governed by interactions of the linker and cap regions rather than by the conserved zinc-binding group itself.<\/jats:p>","DOI":"10.3390\/molecules31101650","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:04:09Z","timestamp":1778763849000},"page":"1650","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Zinc Affinity of Benzamide-Based Histone Deacetylase Inhibitors: A DFT Study"],"prefix":"10.3390","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3637-6897","authenticated-orcid":false,"given":"Nikolay","family":"Toshev","sequence":"first","affiliation":[{"name":"Department of Bioorganic Chemistry, Faculty of Pharmacy, Medical University of Plovdiv, 15A Vassil Aprilov Blvd., 4002 Plovdiv, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9527-9854","authenticated-orcid":false,"given":"Kristiyan","family":"Velichkov","sequence":"additional","affiliation":[{"name":"Medical Faculty, Medical University of Plovdiv, 15A Vassil Aprilov Blvd., 4002 Plovdiv, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6423-5998","authenticated-orcid":false,"given":"Yordanka","family":"Uzunova","sequence":"additional","affiliation":[{"name":"Department of Bioorganic Chemistry, Faculty of Pharmacy, Medical University of Plovdiv, 15A Vassil Aprilov Blvd., 4002 Plovdiv, Bulgaria"},{"name":"Research Institute, Medical University of Plovdiv, 15A Vassil Aprilov Blvd, 4002 Plovdiv, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Cheshmedzhieva","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Applied Organic Chemistry, Faculty of Chemistry and Pharmacy, Sofia University \u201cSt. Kliment Ohridski\u201d, 1 James Bourchier Blvd., 1164 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todor","family":"Dudev","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Applied Organic Chemistry, Faculty of Chemistry and Pharmacy, Sofia University \u201cSt. Kliment Ohridski\u201d, 1 James Bourchier Blvd., 1164 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of Cancer: The Next Generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41420-024-01803-z","article-title":"Cancer epigenetics: From laboratory studies and clinical trials to precision medicine","volume":"10","author":"Yu","year":"2024","journal-title":"Cell Death Discov."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1126\/science.1063127","article-title":"Translating the histone code","volume":"293","author":"Jenuwein","year":"2001","journal-title":"Science"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2007.02.005","article-title":"Chromatin modifications and their function","volume":"128","author":"Kouzarides","year":"2007","journal-title":"Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2217\/epi.12.3","article-title":"Histone-modifying enzymes: Regulators of developmental decisions and drivers of human disease","volume":"4","author":"Butler","year":"2012","journal-title":"Epigenomics"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.tig.2011.06.006","article-title":"Histone modification: Cause or cog?","volume":"27","author":"Henikoff","year":"2011","journal-title":"Trends Genet."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Verza, F., Das, U., Fachin, A., Dimmock, J., and Marins, M. (2020). Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy. Cancers, 12.","DOI":"10.3390\/cancers12061664"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrg2485","article-title":"The many roles of histone deacetylases in development and physiology: Implications for disease and therapy","volume":"10","author":"Haberland","year":"2009","journal-title":"Nat. Rev. Genet."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Li, G., Tian, Y., and Zhu, W. (2020). The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.576946"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Ruzic, D., Djokovic, N., Srdic-Rajic, T., Echeverria, C., Nikolic, K., and Santibanez, J. (2022). Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14010209"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.molonc.2007.01.001","article-title":"The role of histone deacetylases (HDACs) in human cancer","volume":"1","author":"Ropero","year":"2007","journal-title":"Mol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1021\/acs.chemrev.8b00201","article-title":"Targeting metalloenzymes for therapeutic intervention","volume":"119","author":"Chen","year":"2018","journal-title":"Chem. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1042\/bj20021321","article-title":"Histone deacetylases (HDACs): Characterization of the classical HDAC family","volume":"370","author":"Caron","year":"2003","journal-title":"Biochem. J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.str.2004.04.012","article-title":"Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases","volume":"12","author":"Somoza","year":"2004","journal-title":"Structure"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"15064","DOI":"10.1073\/pnas.0404603101","article-title":"Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor","volume":"101","author":"Vannini","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.apsb.2023.02.007","article-title":"Targeting histone deacetylases for cancer therapy: Trends and challenges","volume":"13","author":"Liang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12094-025-03995-x","article-title":"Clinical progress and functional modalities of HDAC inhibitor-based combination therapies in cancer treatment","volume":"28","author":"Talom","year":"2026","journal-title":"Clin. Transl. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ejmech.2016.05.047","article-title":"Inside HDACs with more selective HDAC inhibitors","volume":"121","author":"Roche","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"108700","DOI":"10.1016\/j.bioorg.2025.108700","article-title":"Hydroxamic acid hybrids as histone deacetylase inhibitors for cancer therapy: An update (2022 to date)","volume":"163","author":"Cheng","year":"2025","journal-title":"Bioorganic Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"859","DOI":"10.4155\/fmc-2023-0122","article-title":"Key structural requirements of benzamide derivatives for histone deacetylase inhibition: Design, synthesis and biological evaluation","volume":"16","author":"Cheshmazar","year":"2024","journal-title":"Future Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"103569","DOI":"10.1016\/j.drudis.2023.103569","article-title":"Fatty acids as histone deacetylase inhibitors: Old biochemistry tales in a new life sciences town","volume":"28","author":"Ediriweera","year":"2023","journal-title":"Drug Discov. Today"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1586\/era.10.88","article-title":"Romidepsin: A new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors","volume":"10","author":"Grant","year":"2010","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Pires, G., Tolomeu, H., Rodrigues, D., Lima, L., Fraga, C., and Pinheiro, P. (2025). Drug Discovery for Histone Deacetylase Inhibition: Past, Present and Future of Zinc-Binding Groups. Pharmaceuticals, 18.","DOI":"10.20944\/preprints202503.2208.v1"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"7698","DOI":"10.1021\/acs.jmedchem.3c00226","article-title":"The Zinc-Binding Group Effect: Lessons from Non-Hydroxamic Acid Vorinostat Analogs","volume":"66","author":"Geurs","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3390\/foundations4030024","article-title":"Experimental and Theoretical Investigation of the Coordination of 8-Hydroxquinoline Inhibitors to Biomimetic Zinc Complexes and Histone Deacetylase 8 (HDAC8)","volume":"4","author":"Baudino","year":"2024","journal-title":"Foundations"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/j.ejmech.2017.10.076","article-title":"The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6\/HDAC8 selectivity","volume":"143","author":"Negmeldin","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"14764","DOI":"10.1021\/acs.jmedchem.2c01276","article-title":"First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids","volume":"65","author":"Karaj","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1016\/j.bmcl.2017.06.033","article-title":"The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6\/8 selectivity","volume":"27","author":"Negmeldin","year":"2017","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ardp.201500472","article-title":"Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid","volume":"349","author":"Bieliauskas","year":"2016","journal-title":"Arch. Pharm."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/cmdc.201500486","article-title":"Why Hydroxamates May Not Be the Best Histone Deacetylase InhibitorsWhat Some May Have Forgotten or Would Rather Forget?","volume":"11","author":"Shen","year":"2016","journal-title":"Chemmedchem"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"35880","DOI":"10.1038\/s41598-025-19717-w","article-title":"Adverse drug reaction profiles of histone deacetylase inhibitors","volume":"15","author":"Begum","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1016\/j.bmcl.2010.03.091","article-title":"Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides","volume":"20","author":"Bressi","year":"2010","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e202100755","DOI":"10.1002\/cmdc.202100755","article-title":"Balancing Histone Deacetylase (HDAC) Inhibition and Drug-likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors","volume":"17","author":"Haschemi","year":"2022","journal-title":"Chemmedchem"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1016\/j.apsb.2023.02.001","article-title":"Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: A multicenter, randomized, double- blind, placebo-controlled, phase 3 trial","volume":"13","author":"Xu","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1200\/JCO.2024.42.16_suppl.1050","article-title":"Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: An overall survival update and long-term safety from the randomised, double-blind, placebo-controlled, phase 3 trial","volume":"42","author":"Wang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S1470-2045(11)70265-0","article-title":"Mocetinostat for relapsed classical Hodgkin\u2019s lymphoma: An open-label, single-arm, phase 2 trial","volume":"12","author":"Younes","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e005871","DOI":"10.1136\/jitc-2022-005871","article-title":"Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation","volume":"11","author":"Marquardt","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/cncr.31791","article-title":"A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer","volume":"125","author":"Eyre","year":"2019","journal-title":"Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s42003-023-04485-y","article-title":"The HDAC inhibitor zabadinostat is a systemic regulator of adaptive immunity","volume":"6","author":"Liu","year":"2023","journal-title":"Commun. Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","article-title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma","volume":"26","author":"Shi","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_41","first-page":"1014","article-title":"Oral histone deacetylase inhibitor HBI-8000 (tucidinostat) in Japanese patients with relapsed or refractory non-Hodgkin\u2019s lymphoma: Phase I safety and efficacy","volume":"52","author":"Yoshimitsu","year":"2022","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jsb.2016.06.023","article-title":"Structure of \u2018linkerless\u2019 hydroxamic acid inhibitor-HDAC8 complex confirms the formation of an isoform-specific subpocket","volume":"195","author":"Tabackman","year":"2016","journal-title":"J. Struct. Biol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"9538","DOI":"10.1021\/acs.inorgchem.8b01632","article-title":"Metal-binding isosteres as new scaffolds for metalloenzyme inhibitors","volume":"57","author":"Dick","year":"2018","journal-title":"Inorg. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1021\/acsmedchemlett.1c00584","article-title":"Computational prediction of the binding pose of metal-binding pharmacophores","volume":"13","author":"Karges","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"17161","DOI":"10.1021\/acs.inorgchem.1c02433","article-title":"Evaluating Metal-Ligand Interactions of Metal-Binding Isosteres Using Model Complexes","volume":"60","author":"Seo","year":"2021","journal-title":"Inorg. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1039\/D1SC06011B","article-title":"Salicylate metal-binding isosteres as fragments for metalloenzyme inhibition","volume":"13","author":"Jackl","year":"2022","journal-title":"Chem. Sci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1055\/s-0043-1768613","article-title":"Synthesis and Crystal Structure Analysis of Histone Deacetylase Inhibitor Chidamide","volume":"5","author":"Han","year":"2023","journal-title":"Pharm. Front."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1073\/pnas.050316997","article-title":"Low dielectric response in enzyme active site","volume":"97","author":"Mertz","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"26926","DOI":"10.1074\/jbc.M113.490706","article-title":"Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability","volume":"288","author":"Lauffer","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"11636","DOI":"10.1021\/ja501548p","article-title":"Inhibition and Mechanism of HDAC8 Revisited","volume":"136","author":"Chen","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"7120","DOI":"10.1039\/D5CP00002E","article-title":"Deacetylation mechanism of histone deacetylase 8: Insights from QM\/MM MP2 calculations","volume":"27","author":"Lai","year":"2025","journal-title":"Phys. Chem. Chem. Phys."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"11146","DOI":"10.1021\/ja0010296","article-title":"Tetrahedral vs octahedral zinc complexes with ligands of biological interest: A DFT\/CDM study","volume":"122","author":"Dudev","year":"2000","journal-title":"J. Am. Chem. Soc."},{"key":"ref_53","unstructured":"Frisch, M.J., Trucks, G.W., Schlegel, H.B., Scuseria, G.E., Robb, M.A., Cheeseman, J.R., Scalmani, G., Barone, V., Petersson, G.A., and Nakatsuji, H. (2019). Gaussian, Gaussian, Inc.. version 16, Rev. C.01."},{"key":"ref_54","unstructured":"Andrienko, G.A. (2026, March 03). Chemcraft, Version 1.8, Build 682; Graphical Software for Visualization of Quantum Chemistry Computations. Available online: https:\/\/www.chemcraftprog.com."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"10109","DOI":"10.1021\/la061365l","article-title":"Infrared spectroscopic studies of siderophore-related hydroxamic acid ligands adsorbed on titanium dioxide","volume":"22","author":"Yang","year":"2006","journal-title":"Langmuir"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s11224-008-9338-3","article-title":"Conformational analysis of N-isopropylbenzohydroxamic acids: Crystal structure, DFT, and NMR studies","volume":"19","author":"Przychodzen","year":"2008","journal-title":"Struct. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s00894-018-3651-6","article-title":"Hydroxamic acid derivatives as histone deacetylase inhibitors: A DFT study of their tautomerism and metal affinities\/selectivities","volume":"24","author":"Cheshmedzhieva","year":"2018","journal-title":"J. Mol. Model."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1021\/ja055797e","article-title":"A DFT\/CDM study of metal-carboxylate interactions in metalloproteins: Factors governing the maximum number of metal-bound carboxylates","volume":"128","author":"Dudev","year":"2006","journal-title":"J. Am. Chem. Soc."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1107\/S0907444999007374","article-title":"The geometry of metal-ligand interactions relevant to proteins","volume":"55","author":"Harding","year":"1999","journal-title":"Acta Crystallogr. Sect. D.-Biol. Crystallogr."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/10\/1650\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:04:23Z","timestamp":1778763863000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/10\/1650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":59,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["molecules31101650"],"URL":"https:\/\/doi.org\/10.3390\/molecules31101650","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]}}}